How to use Technologies offered

A search for a cancer, preclinical stage, synthetic opportunity would use the selection "Therapeutics, Diagnostics" in 'Sector', 'Cancerous, neoplasmatic' in 'Disease Category', 'Drugs, Small Molecule' in 'Technology' and 'Preclinical' in 'Development Stage'.

Selection of 'Enabling Technology, Platform Technology' in 'Sector' will identify all kinds of research technologies that can be used in more areas of life sciences than pharmaceuticals only.

Each technology profile gives the name of a company or academic institute as source of the offer, and a link allowing to contact the potential licensor. In most cases a profile includes a pdf covering the available non-confidential information as well as detailed contact data.

Registered users can create non-public notifications profiles which will inform them about new 'Technologies Offered' entries fitting their needs as specified. In addition these profiles allow them to filter the available information more comfortably.

Name

Biomarkers for Diagnosis of Parkinson´s Disease in Skin Biopsies offered by Innovetcis, Frankfurt

Organization name

INNOVECTIS Gesellschaft für Innovations-Dienstleistungen mbH

Profile

Abstract

Expression analysis of several novel bio-markers in skin probes of patients allows the prognosis and diagnosis of all variants of Parkinson’s disease (PD), monitoring of the disease progression and the response to medical treatment.

Background

Parkinson’s disease is a degenerative disorder of the central nervous system. The risk of developing Parkinson syndromes rises with age. Parkinson's disease is widespread, e.g. in Germany with a prevalence estimated between 200.000 and 300.000 people.

Today, the clinical diagnosis of PD involves the monitoring of its cardinal symptoms akinesia, rigidity, tremor and postural instability combined with different medical imaging techniques. Before exitus, no reliable laboratory test is available leading to false diagnosis especially during early stage of disorder.

Invention

Studies from the University Hospital of Frankfurt am Main show that by analysis of skin biopsies of patients the incidence and progress of Parkinson’s disease can be diagnosed. Using fibroblasts isolated from PD mouse models and skin probes from PD patients significant changes of mRNA expression of different genes have been measured. Of interest, mRNA levels of several genes involved in adhesion and differentiation of synapses varied by a factor 3 to 23 as com-pared to controls. Furthermore, it has been found that expression pattern of some biomarkers depend on the disease progression.

Advantages

  • The new data suggest that Parkinson´s disease can be diagnosed and prognosed by analysing easily accessible tissue probes, e.g. skin biopsies.
  • In general, the diagnosis of all variants of PD should be possible.
  • Expression patterns of individual biomarkers can be used to determine the progress of the disease.

Project Status

Using different methods for mRNA quantification mouse fibroblast from PD models and skin biopsies of patients with idiopathic and congenital PD have been analysed.

A German patent application is filed. Owner of the patent is the Johann Wolfgang Goethe-University Frankfurt am Main.

Licensing or assignment of the technology is possible as well as a cooperation for further development of the invention.

Contact

INNOVECTIS Gesellschaft für Innovations-Dienstleistungen mbH
Dr. Otmar Schöller
info(at)innovectis.de

To view the contact information, attachments and url of this profile you have to login into your account or register a new account: Login Register

Your feedback

Please click here to log in to view the complete profile.

 
 

latest entries